INFORMATION FOR CONSUMERS
Home | Consumers | Health Professionals | Regulatory | Other | Hot Topics | Search
Home | Consumers | Health Professionals | Regulatory | Other | Hot Topics | Search
Please read this leaflet carefully before you start to use your medicine. It answers some common questions about Oracort.
Keep the leaflet with the medicine.
You may need to read it again.
This leaflet only applies to Oracort.
Your medicine is called Oracort. The active ingredient is triamcinolone acetonide. Triamcinolone acetonide belongs to the class of medicines called corticosteroids. The medicine has anti-inflammatory, anti-pruritic (anti-itch) and anti-allergic actions which may provide prompt relief of oral tenderness, pain, inflammation and ulceration. The emollient dental paste acts as an adhesive for applying the medicine to your mouth and keeps the medicine in close contact with the lesion being treated while also providing a protective covering.
Make sure it is safe for you to use Oracort. Read the following questions carefully.
Have you previously had an allergic reaction to triamcinolone acetonide or any other ingredient such as gelatin, pectin, carboxymethylcellulose sodium, mineral oil, polyethylene? (An allergic reaction may include rash, itching, swelling or breathing difficulties).
Have you currently got a fungal, viral or bacterial infection in your mouth or throat?
Do you have tuberculosis, a stomach ulcer or diabetes?
Are you pregnant or intend to become pregnant?
Are you currently breast feeding?
Are you taking any other medicine, especially any other preparation that is to be applied to the same area of the mouth?
If you answer YES to any of the above questions or are not sure, do not start treatment. Talk to your doctor, pharmacist or dentist first.
Use your medicine as instructed by your doctor, pharmacist or dentist. Press a small dab (about 6mm) to the lesion (such as an ulcer) in your mouth until a thin film develops. A larger amount may be required for coverage of some lesions. To avoid a granular gritty sensation, dab, do not rub or spread Oracort. Spreading may also cause Oracort to crumble. After application, however, a smooth slippery film develops. Oracort should be applied at bedtime to permit steroid contact with the lesion throughout the night. Depending on how severe your symptoms are, it may be necessary to apply Oracort two to three times a day, preferably after meals. If the lesion that you are treating is not significantly better in seven days, check with your doctor, pharmacist or dentist.
This medicine is for you. Never give it to others. It may harm them, even if their symptoms are the same as yours.
Long term use of Oracort may result in side effects known to occur with steroids that are taken as tablets or injections; for example supressing your natural steroid production. You should consult with your doctor before using Oracort for longer than 7 days.
Local irritation or increased sensitivity may occasionally occur. Oracort should be discontinued and your doctor, pharmacist or dentist consulted.
Other side effects that are not listed above may also occur in some patients. If you notice any other side effects, check with your doctor, pharmacist or dentist.
If your symptoms do not improve within 7 days or if, they become worse, check with your doctor or pharmacist.
Store below 25°C. Do not refrigerate. Keep the tube tightly closed to prevent the dental paste from drying out.
Keep your medicine out of the reach of children.
Do not keep/use this medicine when no longer needed or after its expiry date.
Besides triamcinolone acetonide, Oracort contains gelatin, pectin, carboxymethylcellulose, polyethylene and mineral oil as inactive ingredients.
If you are concerned about any aspect of your treatment with Oracort, talk to your doctor, pharmacist or dentist.
Oracort is made by Taro Pharmaceuticals Inc, Hawthorne, NY 10532, USA in its Canadian manufacturing plant.
Distributed in New Zealand by AFT Pharmaceuticals, Auckland, New Zealand.
Medicine classification: Pharmacist Only Medicine
Date of last revision: May 1999